#vaccine research

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.

Sci-B-Vac may offer more protection for older people and those with a weaker immune system.

People who received the vaccine did, however, show stronger immune responses against the virus.

Ending the week with summaries of research from the 2018 Liver Meeting. I cover hepatitis B vaccination, diet and alcoholic liver disease.

A hep C–like virus in the city’s rodents is being used to create the first animal model of the human disease.

The FDA has once again rejected the California-based biotech’s request to approve Heplisav-B.

New treatments for the hepatitis C virus may have cure rates nearing 100 percent, but one global liver disease expert believes the fight again...